DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Allowable Subject Matter
Claims 1-13 are allowed.
The following is a statement of reasons for the indication of allowable subject matter: Regarding independent claim 1, for an apparatus for cooling a tissue during laser-based procedures, comprising: a gas compressor configured to supply pressurized air and connected to a mixing chamber, a fluid reservoir containing a liquid coolant and connected to the mixing chamber via a volume controlling device; the mixing chamber configured to form a liquid-air mixture by mixing the pressurized air from the gas compressor with the liquid coolant from the fluid reservoir, a chilled chamber connected to the mixing chamber and comprising a thermoelectric cooler (TEC) and a heat sink, the chilled chamber being configured to chill the liquid-air mixture, a single delivery tube connected to the chilled chamber has not been suggested or disclosed in the prior art when combined with the rest of the claim limitations of independent claim 1.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claim(s) 14-17 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kazic et al. (US 20190239938) in view of LePivert (US 6551309).
Regarding claim 14, Kazic discloses a method for cooling a tissue during laser irradiation, comprising:
supplying pressurized air 100 to a mixing chamber 7 (Fig. 1, section 0058, quid and delivery means 6 for the gas, wherein these delivery means combine within a spray nozzle 7),
delivering 5 a controlled amount of a liquid coolant 1 to the mixing chamber 7, thereby forming a liquid-air mixture (section 0059),
chilling the liquid-air mixture in a chilled chamber to a temperature within a specified range (sections 0046-0047),
ejecting, through a nozzle 7 having a single outlet 8, the chilled liquid-air mixture as a conical spray onto the tissue (Fig. 3, Section 0072),
wherein the conical spray covers an area of the tissue approximately equivalent to a maximum spot size of a laser beam on the tissue (Section 0072, the area on the tissue surface to which the spray is directed essentially corresponds to the spot size of the laser beam which is emitted from the hand piece).
However, Kazic doesn’t specifically disclose forming a liquid-air mixture within the mixing chamber. LePivert discloses forming a liquid-air mixture within the mixing chamber 15 (column 4 lines 55-58). This allows for more uniform and controlled cooling liquid-air mixture to be delivered. Therefore it would have been obvious to one of ordinary skill in the art, at the time of the invention, to modify the device of Kazic by adding forming a liquid-air mixture within the mixing chamber as taught by LePivert in order to facilitate more uniform and controlled cooling liquid-air mixture to be delivered from the nozzle.
Regarding claim 15, Kazic discloses the method of Claim 14, wherein
the chilled liquid-air mixture is ejected at a pressure sufficient to achieve a fine mist of atomized droplets without substantial accumulation of liquid on a surface of the tissue (Fig. 2, Section 0070).
Regarding claim 16, Kazic discloses the method of Claim 15, wherein
a liquid-to-air ratio is controlled to maintain rapid evaporation of the atomized droplets upon contact with the tissue , resulting in efficient evaporative cooling (sections 0037, 0070).
Regarding claim 17, Kazic discloses the method of Claim 14, further comprising
positioning a distance gauge between the nozzle and the tissue to ensure optimal spacing for effective spray coverage and cooling of the area of the tissue (section 0073).
Response to Arguments
Applicant’s arguments with respect to claim(s) 14-17 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JON ERIC C MORALES whose telephone number is (571)272-3107. The examiner can normally be reached Monday-Friday 830AM-530PM CST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Hamaoui can be reached at 571-270-5625. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JON ERIC C MORALES/Primary Examiner, Art Unit 3796
/J.C.M/Primary Examiner, Art Unit 3796